NovoCure

NovoCure does not make traditional cancer drugs. Instead, the company uses body-worn electrodes to generate low-intensity Tumor Treating Fields (TTFields) that physically disrupt dividing tumor cells. The glioblastoma device Optune Gio has been approved since 2011 but has plateaued for years near 700M USD in annual revenue.

The real inflection came in late 2024 with the LUNAR readout in non-small cell lung cancer after platinum failure: TTFields plus standard therapy extended median overall survival by 3.3 months versus standard alone. The FDA cleared the indication in October 2024, opening the first TAM expansion beyond brain tumors. Lung cancer is 20 times the size of glioblastoma.

2026 will be the year of the second wave: METIS (brain metastases), PANOVA-3 (pancreatic cancer), and TRIDENT (newly diagnosed glioblastoma with radiation) all deliver readouts that can transform NovoCure from a glioblastoma niche into a true oncology platform, or break the thesis for years.

In the 13F universe, the unusual buyers stand out: Baker Brothers Advisors built a 4.1% position between Q3/2025 and Q1/2026 — their typical setup ahead of a Phase 3 readout. Camber Capital and Janus Henderson Biotech funds also added. BlackRock trimmed 12%, interpreted as passive ETF rebalancing after the 78% rebound from sub-14 USD lows.

Insider activity (Form 4): COO Asaf Danziger sold 110,000 shares at 18.40 USD in February 2026 (10b5-1 plan). More importantly, board member William Doyle (former CEO) bought 50,000 shares at 16.70 USD on the open market in January 2026 — his first open-market buy since 2022. Insider buys after multi-year pauses historically hit ~70% in mid-cap biotech.

Short interest sits at 8.2% of float — moderately high but below the sector median of 11%. A positive METIS readout most likely produces a 25-40% squeeze move.

NovoCure is currently unprofitable (forward P/E of -15×), so classical multiples do not apply. With an EV of about 1.9B USD and a Q1/2026 revenue run-rate of 670M USD, EV/Sales is 2.8× — historically in the lower third of the 5-year range (peak 12× in 2021, trough 1.6× in Q4/2023). Sum-of-parts models from Wells Fargo and Piper Sandler value the pipeline (NSCLC + METIS + PANOVA-3) at 35-45 USD per share on risk-adjusted penetration, roughly 70% upside from the current 21 USD print. Street targets range from 19 USD (BofA, Hold) to 38 USD (Wells Fargo, Buy), median 26 USD.

1. June 2, 2026: ASCO Annual Meeting — PANOVA-3 Phase 3 data on TTFields plus gemcitabine/nab-paclitaxel in pancreatic cancer
2. Q2/2026 (June): METIS topline readout in NSCLC brain metastases — primary endpoint is time to intracranial progression
3. July 30, 2026: Q2/2026 earnings call — first full quarter with US LUNAR launch data and NSCLC penetration curve

NovoCure is a platform bet — not a pill company. If METIS or PANOVA-3 read out positive, you get an oncology hardware story inside 12 months that every strategic acquirer (Medtronic, Stryker, even Roche) will have on the radar. Cash burn risk is real, but 940M USD funds operations through at least mid-2028 — enough runway to see the next three readouts. I hold NVCR as a small pipeline position (1-2% of portfolio) with clear risk management: stop at 14 USD (52-week low), trim at 35 USD (Wells Fargo mid case). If you cannot stomach binary biotech bets, this stock is not for you.